HK Stock Market Move | ASCLETIS-B(01672) rises over 5%; preclinical studies including ASC30_48 FDC presented at ObesityWeek

date
14:07 17/11/2026
avatar
GMT Eight
ASCLETIS-B(01672) rose over 5%. As of press time, it was up 5.26% at HK$4.5, with a turnover of HK$4.1938 million.
ASCLETIS-B(01672) rose over 5%, up 5.26% as of press time at HK$4.5, with a turnover of HK$4.1938 million. On the news front, ASCLETIS-B announced that Ascletis recently presented key preclinical study results at ObesityWeek 2026, held in Washington, D.C. from November 14 to 17, 2026, for the oral small-molecule GIPR agonist ASC48, the GLP-1R/GIPR dual-target oral small-molecule ASC30_48 FDC (a fixed-dose combination of ASC30 and ASC48), and the long-acting injectable GLP-1R/GIPR/GCGR triple-target agonist peptide ASC37. ASC30_48 FDC is an oral small-molecule combination formulation independently developed by Ascletis, targeting GLP-1R and GIPR, and is expected to become a first-in-class once-daily, one-tablet oral therapy for obesity and other metabolic diseases. In addition, preliminary preclinical data indicate that ASC37 shows good efficacy in weight loss and appetite suppression, and has favorable pharmacokinetic properties, supporting its potential to become a best-in-class therapeutic candidate.